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Background and Purpose. Life expectancy data could identify men with favorable post-radiation prostate-specific antigen (PSA)
failure kinetics unlikely to require androgen deprivation therapy (ADT).Materials andMethods. Of 206 men with unfavorable-risk
prostate cancer in a randomized trial of radiation versus radiation andADT, 53 experienced a PSA failure andwere followedwithout
salvage ADT. Comorbidity, age and established prognostic factors were assessed for relationship to death using Cox regression
analyses. Results. The median age at failure, interval to PSA failure, and PSA doubling time were 76.6 years (interquartile range
[IQR]: 71.8–79.3), 49.1 months (IQR: 37.7–87.4), and 25 months (IQR: 13.1–42.8), respectively. After a median follow up of 4.0 years
following PSA failure, 45% of men had died, none from prostate cancer and no one had developed metastases. Both increasing
age at PSA failure (HR: 1.14; 95% CI: 1.03–1.25; 𝑃 = 0.008) and the presence of moderate to severe comorbidity (HR: 12.5; 95%
CI: 3.81–41.0; 𝑃 < 0.001) were significantly associated with an increased risk of death. Conclusions. Men over the age of 76 with
significant comorbidity and a PSA doubling time >2 years following post-radiation PSA failure appear to be good candidates for
observation without ADT intervention.
1. Introduction
Based on the prostate specific antigen (PSA) level, biopsy
Gleason score, and American Joint Commission on Cancer
tumor (T) category, approximately 10%–50% of men will
have evidence of disease recurrence at 10 years following
external beam radiation therapy with or without concurrent
androgen deprivation therapy (ADT) for prostate cancer [1,
2]. In select cases, where men experience both long intervals
to PSA recurrence and slow PSA doubling times, a PSA
rise reflects a local-only failure and salvage local therapy is
an option [3]. For most men with a PSA failure, however,
systemic therapy in the form of ADT is considered to delay
progression to symptomatic metastatic disease.The timing of
initiating ADT following postradiation PSA failure, however,
remains an unanswered question. In light of the protracted
natural history following PSA failure before the development
of clinical symptoms frommetastasis [4], as well as the signif-
icant morbidity associated with long-course ADT in an aging
population with competing risks of death, there is a need
to identify patient subsets who may be followed expectantly
with serial PSA’s and bone scanmonitoring without ADT.We
hypothesized that using a validated comorbidity metric such
as the Adult Comorbidity Evaluation (ACE) 27 Comorbidity
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index, age, and prognostic factors in the PSA failure state, one
may be able to identifymenwho can avoidADT and live their
life with a high likelihood of no progression to metastases.
Factors associated with improved outcomes following
PSA failure after local therapy include prolonged time to
failure [5], slower PSA doubling time [6], and lower Gleason
score [7]. While a randomized trial (NCT00439751) inves-
tigating the timing of ADT initiation following PSA failure
after radiation is underway, we currently lack established
patient characteristics predicting men who can safely avoid
ADT.
We retrospectively studied a cohort of men with unfavor-
able-risk localized prostate cancer enrolled in a prospective
randomized trial of radiation alone or radiation with 6
months of combined ADT where patient comorbidity at
baseline using the ACE-27 comorbidity metric was available
[8].We evaluatedwhether clinical features associatedwith the
risk of death could identify men appropriate for observation
without salvageADT following postradiation PSA recurrence
who would not suffer clinical progression to metastases prior
to death from a nonprostate cancer cause.
2. Materials and Methods
2.1. Initial Treatment, Followup and Description of the Study
Cohort. The cohort is comprised of men enrolled in a
randomized trial of radiation or radiation with 6 months
of combined ADT [8]. At enrollment, all men had local-
ized intermediate or high-risk disease (PSA > 10 ng/mL or
Gleason ≥ 7 and 2002 AJCC clinical T category T1b to
T2b) and workup included central pathology review (AAR),
PSA value, bone scan, and computerized tomographic or
magnetic resonance imaging of the pelvis. The radiation was
delivered using a three-dimensional, two-phase approach
to the prostate and seminal vesicles to a total of 70.35Gy
over 36 fractions. Combined androgen blockade consisted
of two injections of an LHRH agonist (leuprolide acetate
22.5mg every 3 months or goserelin 10.8mg every 3 months)
and a nonsteroidal antiandrogen (flutamide 250mg every
8 hours or bicalutamide 50mg daily, discontinued on day
85 after the second administration of the LHRH agonist).
Baseline comorbidity at the time of study enrollment was
characterized using the ACE-27 instrument [9]. Prior to
PSA failure, men were seen in followup with PSA every 3
months for 2 years, every 6months until 5 years, and annually
thereafter.
Of the initial 206 enrolled in the randomized study, 108
(52%) had evidence of a biochemical failure defined as a
2 ng/mL elevation above the lowest PSA value achieved. Per
protocol recommendation, 53 of those men who had a PSA
that rose to >10 ng/mL were started on salvage ADT for
life. Two men underwent salvage brachytherapy for a local
only recurrence. The remaining 53 participants with PSA
recurrence did not receive salvage ADT either because their
PSA remained <10 ng/mL (𝑛 = 41) or because of significant
comorbid illness (𝑛 = 12) and constitute the study cohort.
At the time of PSA failure, all men had restaging with bone
scan.Thereafter, followup and restagingwere at the discretion
of the treating physician and generally PSAs were obtained
annually and bone scans were obtained for symptoms. Cause
of death was determined by the treating oncologist who
followed the patient from study entry until death. This
retrospective analysis of the prospectively collected study
data was approved by the institute institutional review board.
2.2. Statistical Methods
2.2.1. Patient Characteristics Stratified by Survival Status.
We used descriptive statistics including median values and
interquartile range (IQR) to characterize the study cohort
stratified by survival status. Comparisons of categorical
covariates were made using a Fisher exact test. Continuous
covariates were compared using a Wilcoxon rank sum test
[10]. The interval to PSA failure was calculated from the date
of randomization and the PSA doubling time was calculated
using at least two PSA values >0.2 ng/mL assuming first-
order kinetics.
2.2.2. Risk of All-Cause Mortality. Univariable andmultivari-
able Cox regression analyses [11] were performed to identify
factors associatedwith the risk of death following PSA failure.
We included known patient, treatment, and previously iden-
tified prognostic markers in the model including initial study
treatment arm (radiation alone versus radiation plus ADT),
PSA doubling time (continuous), biopsy Gleason score (≤7
versus ≥8), clinical T category (T1 versus T2), age at PSA
failure (continuous), ACE-27 comorbidity (none or minimal
versus moderate or severe) [9], and interval to PSA failure.
Both the PSA doubling time and time to PSA failure were log-
transformed and treated as continuous measures. Baseline
groups for the categorical variables included radiation alone
treatment arm, biopsy Gleason 7 or less, T1, and no or
minimal comorbidity. Unadjusted and adjusted hazard ratios
(HR) and associated 95% confidence interval (CI) were
calculated for each covariate.
2.2.3. Estimates of All-Cause Mortality. One minus Kaplan-
Meier estimates [12] of overall survival were calculated to
estimate all-cause mortality following PSA failure and were
graphically displayed stratified into three groups using two
factors: the median age at PSA failure and the presence
of moderate to severe comorbidity versus no or minimal
comorbidity using the ACE-27 metric. Comparisons of the
estimates of all-cause mortality between groups were made
by log-rank test.
All 𝑃 values are two-sided and Bonferroni corrections
[13] were made for multiple comparisons. All analyses were
performed using SAS software (version 9.3; SAS Institute,
Cary, NC).
3. Results
3.1. Patient Characteristics Stratified by Survival Status. For
the entire study cohort, the median age at PSA failure,
interval to PSA failure and PSA doubling timewere 76.6 years
(IQR: 71.8–79.3), 49.1months (IQR: 37.7–87.4), and 25months
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Table 1: Comparison of the distribution of the clinical characteristics at the time of initial treatment and at PSA failure for the 53 men in the
study cohort stratified by survival status at time of last followup.
Characteristic Alive, 𝑛 = 29 Dead, 𝑛 = 24 𝑃
Age at PSA failure—median (IQR), yrs 75.7 77.3 0.10
PSA (69.4–78.6) (75.0–80.8)
Doubling time—median (IQR), mo 32.9 (15.0–43.0) 20.3 (10.5–42.6) 0.55
Interval to failure—median (IQR), mo 57.4 (35.0–99.0) 47.2 (38.3–57.9) 0.44
Last PSA level—median (IQR), ng/mL 4.7 (2.9–10.0) 2.4 (1.7–6.9) 0.16
Primary treatment—𝑛 (%)
Radiation 19 (66) 16 (67) 1.0∗
Radiation + ADT 10 (34) 8 (33)
Gleason—𝑛 (%)
≤6 11 (38) 2 (8)
0.02∗7 16 (55) 16 (67)
8–10 2 (7) 6 (25)
T category—𝑛 (%)
T1 13 (45) 10 (42) 1.0∗
T2 16 (55) 14 (58)
Comorbidity—𝑛 (%)
None or minimal 27 (93) 14 (58) 0.004∗
Moderate or severe 2 (7) 10 (42)
PSA: prostate specific antigen; IQR: interquartile range; ADT: androgen deprivation therapy.
∗Fisher exact test 𝑃 value.
(IQR: 13.1–42.8), respectively. Over a median follow up of 4.0
years (IQR: 2.0–12.5) following PSA failure, we observed 24
(45%) deaths, all of causes other than prostate cancer and
no man had evidence of metastatic disease. The median last
followup PSA was 3.6 ng/mL (IQR: 1.8–8.3).
As shown in Table 1, men dead at last followup had a
median age of 77.3 years at PSA failure compared to 75.7 years
for those alive (𝑃 = 0.1). The men who had died were more
likely to havemoderate to severe comorbidity (41% versus 7%;
𝑃 = 0.004) andmore commonly had biopsy Gleason ≥7 (92%
versus 62%; 𝑃 = 0.02). We did not find that other prostate
cancer specific prognostic factors were differential between
those who died and those alive at last followup including PSA
doubling time (20.3 versus 32.9 months; 𝑃 = 0.55), interval
to PSA failure (47.2 versus 57.4 months; 𝑃 = 0.44), and most
recent PSA level (2.4 versus 4.7 ng/mL; 𝑃 = 0.16).
3.2. Risk of All-Cause Mortality. On univariate analysis
(Table 2), factors significantly associated with death in the
cohort of men with PSA recurrence but no salvage ADT use
were age at PSA failure (HR 1.12; 95% CI: 1.02–1.22; 𝑃 = 0.01)
and the presence of moderate to severe comorbidity (HR
5.32; 95% CI: 2.31–12.3; 𝑃 < 0.001). Similarly, on multivariate
analysis (Table 2), only age at PSA failure (AHR: 1.14; 95% CI:
1.03–1.25; 𝑃 = 0.008) and the presence of moderate to severe
comorbidity (AHR: 12.5; 95% CI: 3.81–41.0; 𝑃 < 0.001) were
significantly associated with the risk of death.
3.3. Estimates of All-Cause Mortality. For the purposes of
illustration, we subdivided the cohort into three groups based
on the median age at failure and the presence of moderate to
severe comorbidity and plotted the cumulative incidence of
death (Figure 1). Men older than 76.6 years at the time of PSA
failure and who had moderate to severe comorbidity were
significantly more likely to die compared to men with only
one of those features (𝑃 = 0.003) or men who had neither
adverse feature (𝑃 < 0.001). Specifically, 4 years following
PSA failure, 85.7% (95% CI: 53.5%–99.3%) of men above
the median age and with moderate or severe comorbidity
were dead compared to 16.4% (95% CI: 5.6%–42.7%) of men
younger than the median with no minimal comorbidities.
For those men with either age greater than the median or
moderate or severe comorbidities, but not both factors, the 4-
year mortality was 39.2% (95% CI: 22.1%–64.6%). We could
identify no difference between those without either adverse
feature and those with only one (𝑃 = 0.14).
4. Discussion
In this study, we identify a subset of men with PSA only
recurrences following radiation with or without 6 months
of ADT for unfavorable-risk and localized prostate cancer
who are unlikely to progress to metastatic disease during
their remaining life expectancy despite withholding salvage
ADT. Specifically, we show that men with both a long interval
to PSA failure (median 49 months) and long PSA doubling
time (median 25 months) who are advanced in age (median
76.6 years) with moderate to severe comorbidity appear
unlikely to progress to symptomatic distantmetastatic disease
or die of prostate cancer. Only 14% of this population was
estimated to remain alive 4 years followingPSA failure despite
withholding salvage ADT and all deaths were nonprostate
cancer related.
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Table 2: Unadjusted and adjusted hazard ratios for all-cause mortality following PSA failure.
Clinical factor Number of men Number of events Univariable HR(95% CI) 𝑃
Multivariable
AHR (95% CI) 𝑃
Treatment arm
Radiation 35 16 Ref. — Ref. —
Radiation + ADT 18 8 1.01 (0.43–2.37) 0.99 1.69 (0.68–4.19) 0.26
Gleason
≤7 45 18 Ref. — Ref. —
>7 8 6 2.02 (0.80–5.10) 0.14 0.82 (0.28–2.44) 0.72
Clinical T category
T1 23 10 Ref. — Ref. —
T2 30 14 0.93 (0.41–2.13) 0.87 0.65 (0.25–1.72) 0.39
ACE-27 comorbidity
None or minimal 41 14 Ref. — Ref. —
Moderate or severe 12 10 5.32 (2.31–12.3) <0.001 12.50 (3.81–41.0) <0.001
Age in years at PSA failure 53 24 1.12 (1.02–1.22) 0.01 1.14 (1.03–1.25) 0.008
Interval to PSA failure in months∗ 53 24 1.73 (0.75–3.98) 0.20 2.36 (0.89–6.26) 0.09
PSA doubling time in months∗ 53 24 0.98 (0.60–1.59) 0.92 1.15 (0.63–2.08) 0.66
∗Log-transformed.
ADT: androgen deprivation therapy; PSA: prostate specific antigen.
Age > median and cm mod. to sev.
Age > median and cm mod. to sev. but not both
Age median or less and cm no or min.
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Figure 1: One minus Kaplan Meier estimates of all-cause mortality
following PSA failure for subgroups based on the median age at
failure (76.6 years) and presence or absence of ACE-27 defined
moderate to severe comorbidity (CM).Menolder than themedian at
the time of PSA failure andwho hadmoderate to severe comorbidity
were significantly more likely to die compared to men with only one
of those features (𝑃 = 0.003) ormenwho had neither adverse feature
(𝑃 < 0.001). No significant difference was identified between men
with one or neither risk factor (𝑃 = 0.14). Significance is defined as
𝑃 < 0.0167 per Bonferroni correction.
In a healthy cohort selected for radical prostatectomy
the median time from PSA failure to metastasis is 8 years
and to death from prostate cancer is more than 10 years [4].
Therefore, a better understanding of who, particularly those
with limited life expectancy due to comorbidity, may safely
avoid treatment with salvage ADT is needed. Randomized
trials investigating the role of early versus delayed initiation
of ADT in men found at prostatectomy to have lymph node
involvement [14] and those with advanced prostate cancer
[15] showed a survival advantage to the early initiation of
ADT. How these and other results from men with advanced
disease translate to the population with a rising following
radiation is unclear. Lacking results from a randomized
Canadian trial of early versus delayed ADT in men with
PSA failure following radiation (NCT00439751), decisions
are typically made today in the context of comorbidity
and adverse prostate cancer prognostic factors such as PSA
doubling time and time to PSA failure.
Using these existing prognostic factors to guide treat-
ment, other groups have reported outcomes similar to ours.
Faria and colleagues reported on a cohort of 285 men who
underwent external beam radiationwith or without ADT and
experienced a biochemical failure [16]. Using an approach
similar to the one we report here of avoiding salvage ADT
in men with long intervals to failure (median 30 months)
and slow doubling times (median 26 months), they show
that among 113 men with these characteristics, none had
developed metastatic disease or died of prostate cancer with
nearly 4 years median followup. Klayton and colleagues
report on a cohort of 432 men with a biochemical failure
following external beam radiation with more than 3 years of
followup from failure [17]. They found that salvage ADT was
associated with improved prostate cancer mortality only in
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those men with a PSA doubling time <6 months. A prior
publication from this cohort had reported the development
of distant metastatic disease in only 8% of 89 men with
PSA doubling times >12 months who were not treated with
ADT after biochemical failure [18]. These studies did not
investigate the role of comorbidity.
While this study is strengthened by the use of prospec-
tively collected data on men who were enrolled in a ran-
domized trial, it has several potential limitations. First, the
decision to start or withhold ADT following PSA failure
was based on a PSA level of 10 ng/mL without regards to
the PSA doubling time since the prognostic value of PSA
doubling time was not appreciated at the time the study was
designed in 1994. We attempted to adjust for this issue by
including PSA doubling time in the multivariable model.
Second, with 53 men, the study is not large enough to draw
definitive conclusions about all men in whom salvage ADT
can be withheld; in older and less healthy men, the data
appear robust enough to make this recommendation. While
the follow-up time after PSA failure was relatively long at
a median of 4 years, it remains to be seen how durable
the observed nonprogression to symptomatic disease will be,
especially in younger and healthy patients. Third, we used
the median age in our model based on statistical standards
but at age 76.6 years, the median remaining life expectancy
(RLE) for men in average health is approximately 10 years
based on social security actuarial life tables lending credence
to making a recommendation to withhold ADT in this group
of men with favorable prognostic factors and moderate to
severe comorbidity where RLE would be expected to be
less than 10 years. Finally, the comorbidities were assessed
at enrollment in the study and therefore may not perfectly
match those present at the time of PSA failure; however,
the fact that the ACE-27 score was significantly associated
with the risk of all-cause mortality on multivariate analysis
is reassuring. Whether the interaction between comorbidity
and ADT toxicity can be modified by lifestyle changes is yet
to be tested but has the potential to change our observations.
In summary, our data suggest that older, less healthy
men with both long intervals to PSA failure and PSA
doubling times can safely be spared the morbidity of life-
long ADT following postradiation PSA failure. Given the
proposed interaction between comorbidity andADTuse [19],
withholdingADT in thesemenmay actually prolong their life
span. Ultimately, it will take the results of randomized trials
where comorbidity is stratified for to definitively answer the
question of when and in whom ADT is beneficial following
PSA failure.
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